HUTCHMED Highlights Presentation of Phase III Data on

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13)...

Related Keywords

Japan ,Shanghai ,China ,Australia ,United States ,Panmure ,Victoria ,Hong Kong ,American ,Atholl Tweedie ,Ben Atwell Alex Shaw ,Daphne Zhang ,Freddy Crossley ,Zhou Yi ,Rui Hua Xu ,American Society Of Clinical Oncology ,Nasdaq ,China Limited ,Stock Exchange Of Hong Kong ,Exchange Commission ,Linkedin ,China National Reimbursement Drug List ,Journal Of The American Medical Association ,American Society ,Clinical Oncology ,Plenary Series Session ,New Drug Application ,China National Medical Products Administration ,Fruquintinib Approval ,American Medical Association ,Securities Litigation Reform Act ,Stock Exchange ,Alex Shaw ,Global Cancer Observatory ,Stomach Cancer Fact ,Accessed April ,China Fact ,Nasdaq Hcm ,Hutchmed China Limited ,